淀粉样蛋白(真菌学)
临床试验
医学
淀粉样β
疾病
抗体
内科学
免疫学
病理
作者
Leonardino A. Digma,Joseph R. Winer,Michael D. Greicius
摘要
With the FDA approval of aducanumab and lecanemab, and with the recent statistically significant phase 3 clinical trial for donanemab, there is growing enthusiasm for anti-amyloid antibodies in the treatment of Alzheimer’s disease. Here, we discuss three substantial limitations regarding recent anti-amyloid clinical trials: 1) there is little evidence that amyloid reduction correlates with clinical outcome, 2) the reported efficacy of anti-amyloid therapies may be explained by functional unblinding, and 3) donanemab had no effect on tau burden in its phase 3 trial. Taken together, these observations call into question the efficacy of anti-amyloid therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI